ABEO - ABEONA THERAPEUTICS INC.

4.18
-0.190   -4.545%

Share volume: 673,689
Last Updated: 04-10-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.01%

PREVIOUS CLOSE
CHG
CHG%
$4.37
-0.19
-0.04%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
23%
Profitability 0%
Dept financing 21%
Liquidity 50%
Performance 40%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-7.21%
1 Month
-23.44%
3 Months
-25.49%
6 Months
-34.79%
1 Year
-46.34%
2 Year
43.64%
Key data
Stock price
$4.18
P/E Ratio 
0.00
DAY RANGE
$3.97 - $4.34
EPS 
-$1.55
52 WEEK RANGE
$3.05 - $8.45
52 WEEK CHANGE
-$44.64
MARKET CAP 
242.134 M
YIELD 
N/A
SHARES OUTSTANDING 
43.314 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.40
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$986,795
AVERAGE 30 VOLUME 
$664,887
Company detail
CEO: Vishwas Seshadri
Region: US
Website: abeonatherapeutics.com
Employees: 90
IPO year: 1980
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Abeona Therapeutics Inc. develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A.

Recent news
loading